Sign In
Buy FLGT
$16.55
-3.66 (-18.11%)
At Close: Jul 31, 2026
Fulgent Reports Third Quarter 2024 Financial Results
07:00am, Friday, 08'th Nov 2024
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a th
Fulgent to Participate in Upcoming Conferences
08:00am, Tuesday, 05'th Nov 2024
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ:FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a the
Fulgent Genetics (FLGT) Surges 5.8%: Is This an Indication of Further Gains?
09:10am, Friday, 01'st Nov 2024
Fulgent Genetics (FLGT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price inc
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a th
Fulgent to Announce Third Quarter 2024 Financial Results on Friday, November 8, 2024
04:05pm, Thursday, 17'th Oct 2024
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a the
Fulgent Genetics: An NCAV Pick With Profit And Growth Potential
11:32am, Wednesday, 25'th Sep 2024
Fulgent Genetics is transitioning from a diagnostic business to a fully integrated healthcare company, with a focus on oncology. Despite past reliance on COVID-19 test revenues, Fulgent's core busines
Fulgent Genetics: Core Growth Re-Acceleration Will Be The Critical Catalyst
12:05pm, Monday, 09'th Sep 2024
Fulgent Genetics' core revenue grew just 3% in H1 2024, with full-year guidance of $280 million implying a step-up to 11% growth in H2 and 7% for FY 2024. Growth in precision diagnostics (+35% in H1 2
Fulgent Genetics (FLGT) Upgraded to Buy: What Does It Mean for the Stock?
01:00pm, Tuesday, 13'th Aug 2024
Fulgent Genetics (FLGT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
How Much Upside is Left in Fulgent Genetics (FLGT)? Wall Street Analysts Think 27.22%
10:55am, Tuesday, 13'th Aug 2024
The mean of analysts' price targets for Fulgent Genetics (FLGT) points to a 27.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among
Fulgent Genetics, Inc. (FLGT) Beats Q2 Earnings and Revenue Estimates
09:17am, Friday, 02'nd Aug 2024
Fulgent Genetics, Inc. (FLGT) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of a loss of $0.31 per share. This compares to loss of $0.08 per share a year ag
Fulgent Reports Second Quarter 2024 Financial Results
07:00am, Friday, 02'nd Aug 2024
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a th
Fulgent Genetics (FLGT) Soars 6.6%: Is Further Upside Left in the Stock?
05:41am, Thursday, 18'th Jul 2024
Fulgent Genetics (FLGT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength dow
PRESS RELEASE - 10/06/2024, 07:00 CEST Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing Mechelen, Belgium 10 June 2024 – Biocartis NV (
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Pharma, a subsidiary of Fulgent Genetics, Inc. (NASDAQ: FLGT) and a leading nanobiotechnology company specializing in innovative cancer therapeutics, today a
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Pharma, a subsidiary of Fulgent Genetics, Inc. (NASDAQ: FLGT) and a leading nanobiotechnology company specializing in innovative cancer therapeutics, today a
